Yüksel Kucukzeybek

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM Trastuzumab, a chemotherapeutic agent used in the treatment of breast cancer. has been shown to induce subclinical left ventricular (LV) dysfunction during a three to six month period as evidenced by strain echocardiographic examination without any change occurring in the ejection fraction of LV. The present study evaluated the presence of subclinical(More)
  • 1